What it sells
Building programmable therapeutics for the immune system
Business model breakdown
Trigger: what makes them buy now?
UnverifiedNeed for programmable, target-specific immune-system therapeutics for cancer, autoimmunity and infection.
Economics: what it saves and how it charges
Pre-commercial biotech: raised $7M+ seed from Felicis, Refactor and Y Combinator (2024); expected value from licensing/partnering or own drug development.
Distribution: how it reaches customers
No commercial product; founders said they plan to build their own pharma company rather than join Big Pharma.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.